Dose Dependent Biological Effects of Idarubicin in HL-60 Cells: Alterations of the Cell-Cycle and Apoptosis

Mareková, Martina; Vávrová, Jiřina; Vokurková, Doris

doi:10.14712/18059694.2019.116

Acta Medica > Archive > 2000, Vol. 43 > Issue 2 > Dose Dependent Biological Effects of…

Acta Med. 2000, 43: 69-73

https://doi.org/10.14712/18059694.2019.116

Dose Dependent Biological Effects of Idarubicin in HL-60 Cells: Alterations of the Cell-Cycle and Apoptosis

Martina Mareková^a, Jiřina Vávrová^b, Doris Vokurková^c

^aCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Medical Biochemistry, Hradec Králové, Czech Republic
^bPurkyně Military Medical Academy, Hradec Králové, Institute of Radiobiology and Immunology, Hradec Králové, Czech Republic
^cUniversity Teaching Hospital in Hradec Králové, Institute of Clinical Immunology and Allergology, Hradec Králové, Czech Republic

Received February 1, 2000
Accepted March 1, 2000

TP-53 deficient cells of human leukaemia HL-60 die by massive apoptosis after treatment by high (50-100 nmol/l) doses of DNA damaging agent Idarubicin, regardless of the cell-cycle phase, in which they are affected. In contrary, after relatively low dose 10 nmol/l the cells die after cell-cycle arrest in G₂ phase. The results show, that apoptosis induced by idarubicin could appear independently of the cell-cycle phase and that period in which apoptosis is observed is related to the dose of Idarubicin.

Keywords

HL-60, Idarubicin, Apoptosis, G2 cell-cycle arrest.

Funding

This work was supported by grants from the Czech Ministry of Defence (MO66020398129) and from Grant Agency of Charles University (GA UK 279/98) and in part by research project J13/98: 111500001.